Sign in
Taking people in United StatesNo phase

Tests a home pulsed electromagnetic device in people with mild to moderate dementia

Tests a home electromagnetic device in people with mild to moderate dementia over 120 days.

Key facts

Who runs it
Herrick Medical LLC
Where
Boca Raton, United StatesSee the site
Trial code
Registry title
Pulsed Electromagnetic Field Treatment With Dementia Patients
Status
Recruiting
People taking part
48 people, planned
Started
1 Apr 2025
Expected to end
30 Sept 2027
Type of study
Interventional
Treatments tested
  • ECHS AD Device
Record updated
17 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 to 100 with mild to moderate Alzheimer's disease, Lewy body dementia or vascular dementia. They treat themselves at home with a pulsed electromagnetic device for 120 days.

Age
50 to 100 years
Sex
All sexes. Women must be post-menopausal.
Disease stage
Mild to moderate Alzheimer's disease, Lewy body dementia or vascular dementia, with a global CDR of 0.5 or 1 and an MMSE score between 16 and 26.
Earlier treatment
If taking a cholinesterase inhibitor or memantine: prescribed for at least 3 months, with a stable dose for at least 60 days. Anti-amyloid antibody treatment must have ended at least 3 months before baseline.

Main reasons for not taking part

  • History of epileptic seizures or epilepsy
  • Frontotemporal dementia
  • Metal implants in the head, except in the mouth
  • Currently taking anti-amyloid monoclonal antibodies
  • No study partner available for interview

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age ≥ 50 years 2.2. Patients diagnosed with mild to moderate AD/ADRD including Alzheimer's disease, Lewy body dementia, and Vascular dementia - defined as a global CDR of 0.5 or 1 at baseline
  • At least an eighth grade of educational achievement 4. If female, post-menopausal. 5. MMSE score between 16 and 26 (inclusive) 6. Capable of providing consent or having a surrogate (e.g., spouse, family member) capable of providing consent if participant lacks consent capacity 7. Able and willing to comply with the protocol 8. If the participant is receiving a cholinesterase inhibitor and/or memantine, such medication has been prescribed for at least 3 months prior to screening and the dose is stable for at least 60 days prior to screening (that dose needs to be maintained throughout the period of this study) 10. Physical clearance for study participation as evaluated by the clinician

Who cannot take part

  • Currently taking medication that lowers the seizure threshold, excluding blood thinners
  • Is currently taking anti-amyloid monoclonal antibodies (past treatment is allowed if termination of treatment occurred at least 3 months prior to the baseline visit)
  • Major surgery (defined as any major abdominal, vascular or thoracic surgery requiring general anesthesia and resulting in a period of >1 week hospitalization) within 4 weeks
  • Participation in another clinical trial within the previous 30 days
  • Metal implants in the head, (i.e., cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants in mouth
  • History of epileptic seizures or epilepsy
  • Has Frontotemporal Dementia
  • Presence of depression, bipolar disorder, a psychotic disorder, or any other neurological or psychiatric condition (whether now or in the past), which the Investigator finds as interfering with the study
  • Alcoholism or substance use disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation
  • Criteria to exclude participants from the blood draw study:; Any condition that may significantly increase risks associated with blood draws
  • The patient lacks capacity to consent to study participation and no surrogate is available to provide consent
  • The patient does not have a study partner who would be available for interview
  • Severe agitation that would interfere with study procedures
  • Head anatomy that interferes with the fit of the treatment device

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 100 years old?

Where in United States

  • University of MiamiBoca Raton, United StatesContact: Magdalena Tolea, PhDTaking people

About the trial

What the trial wants to find out

An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.

The group in the trial

  • Active ECHS AD deviceTreatment being tested

    Experimental intervention arm

    Treatment: ECHS AD Device

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of PEMF Treatment on Patients With Mild to Moderate Dementia in a Controlled Pilot Study
Plain-language title
Tests a home pulsed electromagnetic device in people with mild to moderate dementiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06862557, who can take part
Record updated
17 September 2026